Published: Wed, January 17, 2018
Finance | By Loren Pratt

Johnson & Johnson (JNJ) is Brightworth's 6th Largest Position


About 29.57 million shares traded or 9.26% up from the average. Fate Therapeutics, Inc. (NASDAQ:FATE) has risen 166.12% since January 17, 2017 and is uptrending. It has underperformed by 16.70% the S&P500.

Joel Isaacson & Company Llc increased its stake in New Residential Invt Corp (NRZ) by 139.85% based on its latest 2017Q3 regulatory filing with the SEC. Capital World Investors now owns 22,025,323 shares of the company's stock valued at $2,671,672,000 after buying an additional 2,050,323 shares during the last quarter. The institutional investor held 218,506 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $28.41 million, up from 214,721 at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Fate Therapeutics Inc for a number of months, seems to be less bullish one the $333.93 million market cap company.

On Wednesday, Shares of Johnson & Johnson (NYSE: JNJ) expressed a change of 0.18% and is now trading at $147.13.


Stoneridge Investment Partners Llc, which manages about $1.01B and $635.96 million US Long portfolio, decreased its stake in Pandora Media Inc (NYSE:P) by 45,895 shares to 27,926 shares, valued at $215,000 in 2017Q3, according to the filing. HealthStream, Inc. (HSTM) has risen 29.68% since January 16, 2017 and is uptrending. It has outperformed by 13.19% the S&P500.

Johnson & Johnson's Average Earnings Estimate for the current quarter is $1.99, according to consensus of 14 analysts. They are also projecting the Low EPS estimate of $1.87 and the High EPS estimate of $2.11. Net profit margin of Johnson & Johnson (JNJ) was recorded at 21.3 percent, operating profit margin was 26.1 percent, while gross profit margin stands at 68.3 percent. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. Therefore 52% are positive. During the same period in the prior year, the business earned $1.68 EPS. analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current year. The stock of Johnson & Johnson (NYSE:JNJ) has "Outperform" rating given on Wednesday, January 25 by RBC Capital Markets. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Tuesday, August 15. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Friday, July 14. Finally, Vetr upgraded Johnson & Johnson from a "hold" rating to a "buy" rating and set a $147.14 price target on the stock in a research note on Wednesday, December 20th. As per Thursday, July 20, the company rating was maintained by Stifel Nicolaus. The company was maintained on Wednesday, October 19 by UBS. The rating was maintained by Argus Research with "Buy" on Wednesday, April 20. BMO Capital Markets initiated the shares of FATE in report on Tuesday, April 12 with "Outperform" rating. The firm has "Buy" rating given on Sunday, August 27 by RBC Capital Markets.

Investors sentiment increased to 0.7 in Q3 2017. Its the same as in 2017Q2. It is flat, as 45 investors sold JNJ shares while 871 reduced holdings. only 111 funds opened positions while 645 raised stakes. Davenport And Co Ltd Com invested in 381,468 shares or 0.74% of the stock. 1,980 were accumulated by Inspirion Wealth Advsr Ltd Liability Corporation. The California-based San Francisco Sentry Inv Gp (Ca) has invested 1.5% in Johnson & Johnson (NYSE:JNJ). Hirtle Callaghan & Com Limited Liability holds 15,002 shares. Magellan Asset Limited reported 327 shares. Cowen & Co maintained Johnson & Johnson (NYSE:JNJ) rating on Thursday, August 24. The firm owned 32,795 shares of the company's stock after buying an additional 365 shares during the period. Mckinley Capital Management Delaware has invested 1.96% in Johnson & Johnson (NYSE:JNJ). Capital World Investors boosted its position in shares of Johnson & Johnson by 10.3% in the second quarter. The legal version of this piece can be accessed at https://stocknewstimes.com/2018/01/17/franklin-parlapiano-turner-welch-llc-buys-1435-shares-of-johnson-johnson-jnj.html. Laffer Invs accumulated 6,086 shares. Bancshares Pictet Cie (Asia) Ltd holds 4.75% or 77,500 shares. The New York-based Strategic Advisors Lc has invested 3.15% in Johnson & Johnson (NYSE:JNJ). Rand Wealth Lc holds 122,501 shares or 1.84% of its portfolio. Supplemental Annuity Collective Tru Of Nj has invested 1.82% in Johnson & Johnson (NYSE:JNJ). (JPM) analysts on average have given a price target of $108.54 on JPM stock. Therefore 77% are positive. Manx Telecom had 30 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was initiated by Roth Capital on Thursday, September 22 with "Buy". The firm has "Buy" rating by S&P Research given on Wednesday, October 14. (NASDAQ:AAPL) rating on Wednesday, January 27. KeyBanc Capital Markets has "Overweight" rating and $136 target. Keefe Bruyette & Woods maintained New Residential Investment Corp. Zacks downgraded the stock to "Hold" rating in Monday, September 7 report. FBR Capital maintained New Residential Investment Corp. The company has its outstanding shares of 2.66 Billion. Wells Fargo upgraded it to "Buy" rating and $149.0 target in Monday, October 9 report. Spectrum Asset (Nb Ca) owns 2,131 shares for 0.24% of their portfolio. Finally, Ameriprise Financial Inc. grew its stake in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Its up 0.34, from 0.86 in 2017Q2. It improved, as 36 investors sold ADSK shares while 132 reduced holdings. 17 funds opened positions while 17 raised stakes. (NASDAQ:ADSK) for 4.85M shares. State Board Of Administration Of Florida Retirement System holds 0% of its portfolio in Intrexon Corporation (NYSE:XON) for 77,176 shares. It also upped Prudential Finl Inc (NYSE:PRU) stake by 4,073 shares and now owns 23,575 shares. Susquehanna Llp has 543,265 shares. There has been an observed change of -12.65% in the ownership of the shares in the past six months.

Like this: